Health Care • Biotechnology: Pharmaceutical Preparations
$2.04 ▼ -0.06
(-2.86%)
MKT CAP: $15.9M • VOL: 291.8K
52W L $2 52W H $1,103
ROARABLE / RQD
E • 31/100
PIOTROSKI
1 / 9
JAGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $11.5M | $11.7M | $9.8M |
| YoY Revenue Growth % | -1.5% | +19.8% | — |
| Gross Profit | $7.7M | $9.7M | — |
| Gross Margin % | 67.2% | 83.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$45.9M | -$30.8M | -$34.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$54.0K | -$39.3K | -$41.9K |
| EBITDA (Normalized) | — | -$30.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.7M | -$29.4M | -$33.2M |
| Capital Expenditures (CapEx) | — | $16.0K | — |
| Free Cash Flow (FCF) | -$23.7M | -$29.4M | -$33.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $968.0K | $8.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$18.7M | $9.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JAGX.